PTO/SB/08a (01-10)

Approved for use through 07/31/2012, OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09423698		
Filing Date		2000-02-10		
First Named Inventor Odile		Leroy		
Art Unit		1645		
Examiner Name Patric		ia Ann Duffy		
Attorney Docket Number		99-849-A		

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ument	Relev	s,Columns,Lines where vant Passages or Relev es Appear	
	1									
If you wis	h to ad	d additional U.S. Pate	ent citatio	n inform	ation pl	Lease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUB	LICATIONS			
Examiner Initial*	Cite N	No Publication Number	Kind Code ¹	Publication Date		Name of Pate of cited Docu	entee or Applicant ument	Pages,Columns,Lines where Relevant Passages or Relev- Figures Appear		
	1									
If you wis	h to ad	d additional U.S. Pub	lished Ap	plication	citatio	n information p	please click the Ad	d butto	n.	
				FOREIG	SN PAT	ENT DOCUM	IENTS			
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T 5
	1	03/051392	wo		A2	2003-06-26	GlaxoSmithKline Biologicals S.A.			
If you wis	h to ad	d additional Foreign F	Patent Do	cument	citation	information p	Iease click the Add	buttor	1	
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS			
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.					T 5			

(Not for submission under 37 CFR 1.99)

Application Number		09423698
Filing Date		2000-02-10
First Named Inventor Odile		Leroy
Art Unit		1645
Examiner Name Patric		ia Ann Duffy
Attorney Docket Number		00.840.0

1	Steinhoff, M.C. et al. (1994) A randomized comparison of three bivalent Streptococcus pneumoniae glycoprotein conjugate vaccines in young children: effect of polysaccharide size and linkage characteristics. Pediatr. Infect. Dis. J. Vol. 13 (5), pages 368-372.	
2	Chiu, S.S. et al. (1995) Safety and immunogenicity of a pentavalent pneumococcal conjugate vaccine (PPCV) in healthy boddlers. Presented at the 35th Intersc. Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G71, page 171.	
3	Daum, R.S. et al. (1995) Immunogenicity of S Pneumoniae oligo- and polysaccharide- CRM197 conjugate vaccines in healthy US infants. Presented at the 35th Intersc Conf. Antimicrob. Agents and Chemotherapy, San Francisco Abstr G 65, page 170.	
4	O'Brien, K.L. et al. (1996) Immunologic priming of young children by pneumococcal glycoprotein conjugate but not polysaccharide, vaccines Peditar. Infect. Dis. J. Vol. 15 (5) pages 425-430.	
5	Rennels, M.B. et al. (1996) Abstract from Immunogenicity and Safety of 7-Valent Pneumococcal-CRM-197 Conjugate Vaccine. Pediatric Research, Vol. 39 (4) part 2, page 183A. Asbtr 1082.	
6	Shelly, M.A. et al. (1997) Comparison of pneumococcal polysaccharide and CRM197 conjugated pneumococcal oligosaccharide vaccines in young and elderly adults Infection & Immunity Vol. 65(1) pages 242-247.	
7	Kennedy, D. et al. (1994) Immunologic response of 12-18 months old children to licensed pneumococcal polysaccharide vaccine (PS) primed with Streptococcus pneumoinae 19F conjugate vaccine (CV). Presented at the 34th Interse Conf. Antimicrob. Agents and Chemotherapy Orlando Abstract G88, page 236.	
8	Nieminen, T. et al. (1994) Mucosal and serum immune response to tetravalent pneumococcal (SPn) conjugate vaccines (SpnD and SpnT) in adults. Presented at the 34th Intersc. Conf. Antimicrob. Agents and Chemotherapy Abstract G89, page 236.	
9	Portier, H. et al. (1994) Serum antibody response to a tetravalent pneumococcal tetanus toxoid conjugate vaccine in adult volunteers. Presented at the 34th Intersc. Conf. Antimicorb. Agents and Chemotherapy Abstract G91, page 236.	
10	Keyserling, H. et al. (1994) Immunogenicity of type 14 conjugate vaccine in infants. Presented at the annual meeting of the American Pediatric Society/Society for Pediatric Research Seattle, WA. Abstract 1087, page 184A.	
11	Kennedy, D. et al. (1994) Immunologic response to licensed pneumococcal polysaccharide vaccine (PS) in infants primed with heptavalent Streptococcus pneumoniae conjugated vaccine. Presented at the 34th Intersc. Conf. Antimicrob. Agents in Chemotherapy, Orlando Abstract G90, page 236.	

(Not for submission under 37 CFR 1.99)

Application Number		09423698		
iling Date		2000-02-10		
irst Named Inventor Odile		Leroy		
Art Unit		1645		
Examiner Name Patrici		ia Ann Duffy		
Horney Docket Number		00.840. A		

12	Kayhty, H. et al. (1995) Pneumococcal polysaccharide-menigococcal outer membrane protein complex conjugate vaccine is immunogneic in infants and children. J. Infect. Dis Vol. 172, pages 1273-1278.	
13	Dagan, Ron et al. (1996) Reduction of Nasopharyngeal Carriage of Pneumococci during the Second Year of Life by a Heptavalent Conjugate Pneumococcal Vaccine. The Journal of Infectious Diseases Vol. 174, pages 1271-1278.	
14	SOOD, RAMESH K., ET AL., "Capsular Polysaccharide-Protein Conjugate Vaccines," Research Focus Reviews, DDT, September 1996, pages 381-387, vol. 1, no. 9, Elsevier Science Ltd.	
15	SARNAIK, SHARADA MD, ET AL., "Studies on Pneumococcus Vaccine Alone or Mixed With DTP and on Pneumococcus Type 6B and Haemophilis Influenzae Type b Capsular Polysaccharide-Tetanus Toxold Conjugates in Two Five-Year-Old Children With Sickle Cell Anemia," Pediatric Infect. Dis. J., vol. 9, pp 181-6 (1990).	
16	ANDREW, P.W., ET AL., "Pneumococcal Vaccines," Freer et al. (Eds.), Bacterial Protein Toxins, Zbl. Bakt. Suppl. 24, 1994, pages 453-466, Gustave Fischer, Stuttgart, Jena, New York.	
17	DAGAN, RON, ET AL., "Reduction of Pneumococcal Nasopharyngeal Carriage in Early Infancy After Immunization with Tetravalent Pneumococcal Vaccines Conjugated to Either Tetanus Toxoid or Diphtheria Toxoid," Pediatr Infect. Dis. J., 1997, pages 1060-1064, vol. 16, no. 11, Williams & Wilkins.	
18	LINDBERG, A. A., "Recent Trends in the Developments of Bacterial Vaccines," Brown F. (ed): New Approaches to Stabilisation of Vaccines Potency. Dev Biol. Stand. Basel, Karger, 1996, pages 59-71, vol. 87.	
19	GREENBERG, DAVID, P., ET AL., "Factors Influencing the Immunogenicity of a Pneumococcal Conjugate Vaccine in Infants + 709," Pediatric Research: April 1997 - Volume 41 - Issue 4, Part 2 - p 121; 1997 Abstracts The American Pediatric Society and The Society for Pediatric Research.	
20	Ahman et al., Abstracts of the 35th ICAAC, 1995, G69, "Immunogenicity of tetravalent pneumococcal (Pnc) conjugate vaccines (PndC, PncT) in Finnish infants.	
21	Schutze et al, 1985, J1, Vol. 135 (4), pp. 2319-2322	
22	DE VELASCO, Alonso, et al., "Microbiological Reviews, 1995, pp. 591-603	

(Not for submission under 37 CFR 1.99)

Application Number		09423698
Filing Date		2000-02-10
First Named Inventor Odile		Leroy
Art Unit		1645
Examiner Name	Patric	ia Ann Duffy
Attorney Docket Number		99-849-A

23	Insel, 1995, Annuals New York Academy of Science, pp. 35-47.	
24	GALELLI, et al., 1990, Jl., pp. 2397-2405.	
25	BARINGTON, et al., 1993, Infection and Immunity, Vol. 61 (2), pp. 432-438	
26	DI JOHN, et al., 1989, The Lancet, December 16, pp. 1415-1418.	
27	LECLERC, et al., 1990, Jl, Vol. 145 (5), pp. 1343-1349.	
28	CLEMENS, et al., 1995, Annuals New York Academy of Science, pp.255-266.	
29	MOLRINE, et al., 1995, Annals of Internal Medicine, Vol. 123, pp. 828-834.	
30	ANDERSON, et al., 2003, Vaccine, Vol. 21, pp.1554-1559	
31	PEETERS, et al., 1996, Methods In Molecular Medicine, Vaccine Protocols, pp. 111-133.	
32	ANDRE, 1999, Combination vaccines based on DTP, Novel enabling Technologies for Vaccine development, London, 26-27 January 1999.	
33	ANDERSON, et al., 1989, J. Immunol., Vol. 142(7), pp. 2464-2468	

(Not for submission under 37 CFR 1.99)

Application Number		09423698
Filing Date		2000-02-10
First Named Inventor Odile		Leroy
Art Unit		1645
Examiner Name Patrici		ia Ann Duffy
Attorney Docket Number		99-849-A

34	BUTLER, et al., 1994, J. Infect Dis., Vol. 171(4), pp. 885-889.	
35	DAGAN, et al., 2004, Pediatr Infect Dis J, Vol. 23, pp. 91-98	
36	ELLIS and GRANOFF, 1994, Preface to developmnet and clinical uses of Haemophilus b conjugate vaccines, Marcel Dekker Inc.	
37	ESKOLA et al., 1996, Lancet, Vol. 348, pp. 1688-1692.	
38	TODAR, Kenneth, Department of Bacteriology, University of Wisconsin, Todar's online textbook of bacteriology, 2002, Immune defense against microbial pathogens.	
39	SVENSON and LINDBERG, 1978, J. Immunol. Meth., Vol. 25(4), pp. 323-335.	
40	SVENSON and LINDBERG, 1981, Infect. Immun., Vol. 32(2). pp. 490-496.	
41	WUORIMAA, et al., 2001, J. Infect. Dis., Vol. 184(9), pp. 1211-1215.	
42	WUORIMAA, et al., 2005, Vaccine, Vol. 23, pp. 5328-5332.	
43	SCHNEERSON, et al., 1984, Infect. Immun., Vol. 45(3), pp. 582-591.	
44	CHO, et al., 1995, 35th ICAAC San Francisco, p. 172, abstract.	

(Not for submission under 37 CFR 1.99)

Application Number		09423698
Filing Date		2000-02-10
First Named Inventor Odile		Leroy
Art Unit		1645
Examiner Name Patric		ia Ann Duffy
Attornov Dookst Number		00.040.4

	45	KUO, et	al., July 1995, Inl. Imm., Vol. 63(7), pp	o. 2706-2713.			
	46		al., 1994, Vaccine 94, Pneumococcal on of AIDS, Cold Spring Harbor Press		odern Approaches to N	lew Vaccines Including	
	47		RG AA., 1991, "Polysaccharide vaccir logy, pp. 69-85	es: vaccines needed for	the 1990s", In; R. Norr	by (ed) Frontiers In	
	48						
	49						
	50						
If you wis	sh to a	dd additio	onal non-patent literature documer	t citation information p	lease click the Add b	outton	
			EXAM	INER SIGNATURE			
Examiner Signature			/Patricia Duffy/		Date Considered	10/25/2010	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.